President Donald Trump’s “big, beautiful bill,” which he signed into law earlier this month, includes major wins for business ...

Still, some challenges need to be worked out for companies eying the unique manufacturing process. For SpaceX, its plans ...

SpaceX is planning a stock sale for employees and investors at a per-share price of $212, up from $185 in December, Bloomberg ...

The FDA’s Orphan Drug program is designed to encourage and support the development of treatments for rare diseases or conditions. The designation’s benefits include financial incentives such as tax ...

The SpaceX program is still in the early stages of development and the plans could change. The effort is highly reliant on ...

Republic, a global marketplace for private securities, has launched a new “mirror program” that aims to mint tokens which mirror shares in private firms. The first offering is for a tokenized ...

While it has yet to reach an orbital flight, SpaceX's Starship has been added to SpaceX's contract under NASA's Launch Services Program (LSP).

About $22 billion of SpaceX's government contracts are at risk and multiple U.S. space programs could face dramatic changes in the fallout from Elon Musk and President Donald Trump's explosive ...

President Donald Trump threatened to cut government contracts with Elon Musk amid feud, while the SpaceX CEO suggested decommissioning Dragon.

WASHINGTON (Reuters) -About $22 billion of SpaceX's government contracts are at risk and multiple U.S. space programs could face dramatic changes in the fallout from Elon Musk and President Donald ...

“There's no reason the U.S. can't pick up the pace to match the global clinical research front-runners without compromising safety,” write Brian Finrow and Sandeep Patel.

Drug testing is supposed to be random — but according to insider sources, that's not the case for Elon Musk's federal contractor drug tests.